MedTrace Logo

Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer

NCT00312819 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-08-31

No results posted yet for this study

Summary

Recent studies in laboratory animals demonstrate the ability of disulfiram to significantly inhibit the growth and metastasis of a mouse model of lung cancer. Work with cells in vitro support the idea that this inhibition is mainly due to the inhibition of angiogenesis - the formation of new blood vessels in the tumor. Furthermore, it was found out that the best effect has been obtained when disulfiram has been used not at the highest dose but at an optimal dose, which is smaller. Thus, this trial will assess the addition of disulfiram to chemotherapy in non-small cell lung cancer (NSCLCA).

Conditions

Interventions

DRUG

chemotherapy +/- disulfiram

Sponsors & Collaborators

  • Augusta Hospital, Berlin

    collaborator OTHER

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Hovav Nechushtan, MD, PhD · Hadassah Medical Center Ein Kerem

  • Nili Peylan-Ramu, MD · Hadassah Ein Kerem Medical Center

  • Maya Gotfrid, MD · Meir Medical Center Kfar Saba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00312819 on ClinicalTrials.gov